Inventiva SA (IVA)
| Market Cap | 516.97M |
| Revenue (ttm) | 5.26M |
| Net Income (ttm) | -33.62M |
| Shares Out | 38.63M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $13.27 |
| Previous Close | $13.39 |
| Change ($) | -0.12 |
| Change (%) | -0.90% |
| Day's Open | 13.25 |
| Day's Range | 13.25 - 13.34 |
| Day's Volume | 4,442 |
| 52-Week Range | 9.01 - 19.06 |
News
There are no news available yet.
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. Th... [Read more...]
| Industry Biotechnology | IPO Date Jul 10, 2020 |
| CEO Frederic Cren | Employees 88 |
| Stock Exchange NASDAQ | Ticker Symbol IVA |
Financial Performance
In 2020, Inventiva's revenue was $5.26 million, a decrease of -53.39% compared to the previous year's $11.29 million. Losses were -$33.62 million, 11.3% more than in 2019.